Please wait a minute...
文章检索
预防医学  2020, Vol. 32 Issue (10): 987-991    DOI: 10.19485/j.cnki.issn2096-5087.2020.10.004
  论著 本期目录 | 过刊浏览 | 高级检索 |
云南省男男性行为人群HIV/AIDS病例抗病毒治疗失败基因型耐药分析
阮尉月清1,2, 刘家法1,2, 张米2, 李健健2, 杨壁珲2, 邓雪媚2, 董兴齐1,2
1.昆明医科大学,云南 昆明 650504;
2.云南省传染病医院
Genotypic drug resistance of HIV-infected MSM who failedin antiviral therapy in Yunnan Province
RUAN Weiyueqing*, LIU Jiafa*, ZHANG Mi, LI Jianjian, YANG Bihui, DENG Xuemei, Dong Xingqi
*Kunming Medical University, Kunming, Yunnan 650504, China; Yunnan Provincial Hospital of Infectious Disease
全文: PDF(890 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 了解云南省男男性行为人群艾滋病病毒感染者和艾滋病患者(HIV/AIDS)抗病毒治疗失败的基因型耐药情况,为提高艾滋病抗病毒治疗效果提供依据。方法 选择2014—2019年云南省确证艾滋病病毒1型阳性、经男男性行为感染且抗病毒治疗失败的HIV/AIDS病例为研究对象,采集血浆样本,采用套式反转录聚合酶链反应(RT-nPCR)扩增并测序,采用ContigExpress软件拼接测序片段,整理后序列提交至美国斯坦福大学HIV耐药数据网站比对耐药突变位点,获得序列对8种蛋白酶抑制剂(PIs)、7种核苷类反转录酶抑制剂(NRTIs)和5种非核苷类反转录酶抑制剂(NNRTIs)的耐药程度。结果 共纳入HIV/AIDS病例205例,血浆样本扩增阳性169例,耐药112例,耐药率为66.27%;不同年龄病例中,30~<50岁的耐药率较高,为76.09%;不同基因亚型中,CRF01_AE的耐药率较高,为76.34%;不同用药方案中,采用“齐多夫定+拉米夫定+奈韦拉平”的病例耐药率较高,为77.08%。NNRTIs、NRTIs和PIs耐药率分别为62.72%、49.70%和2.96%;NNRTIs中的奈韦拉平和依非韦仑耐药率较高,分别为62.72%和61.54%。与NNRTIs相关的主要突变位点为K103,37例占21.89%;与NRTIs相关的主要突变位点为M184,67例占39.64%;与PIs相关的主要突变位点为M46L/K,5例占2.96%,且导致奈非那韦高度耐药。结论 云南省男男性行为人群HIV/AIDS病例抗病毒治疗失败的耐药率相对较高,耐药的基因亚型以CRF01_AE为主,NNRTIs类药物耐药率较高,奈韦拉平和依非韦仑尤其需谨慎使用。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
阮尉月清
刘家法
张米
李健健
杨壁珲
邓雪媚
董兴齐
关键词 : 男男性行为者,  艾滋病病毒,  抗病毒治疗,  基因型,  耐药    
Abstract:Objective To learn the genotypic drug resistance of men who have sex with men ( MSM ) with HIV who failed in antiviral therapy in Yunnan Province, in order to provide basis for improving the effect of antiviral therapy. Methods The patients who were infected with HIV-1, homosexual transmitted and failed in antiviral therapy in Yunnan Province from 2014 to 2019 were recruited. Their plasma samples were tested by reverse transcription nested polymerase chain reaction ( RT-nPCR ) , the fragments were spliced using ContigExpress, and the resistance to 8 protease inhibitors ( PIs ) , 7 nucleoside reverse transcriptase inhibitors ( NRTIs ) and 5 non-nucleoside reverse transcriptase inhibitors ( NNRTIs ) were obtained from the HIV drug resistance data website of Stanford University. Results A total of 205 HIV/AIDS cases were included, 169 positive plasma samples were amplified, 112 cases were drug resistant, and the rate of drug resistance was 66.27%. The patients who were aged 30-49 years ( 76.09% ) , had genotype of CRF01_AE ( 76.34% ) or treated by AZT+3TC+NVP ( 77.08% ) had higher resistance rate. The resistance rates of NNRTIs, NRTIs and PIs were 62.72%, 49.70% and 2.96%, respectively; the resistance rates of NVP and EFV in NNRTIs were 62.72% and 61.54%. The main mutation site associated with NNRTIs was K103, accounting for 21.89% ( 37 cases ) ; the main mutation site associated with NRTIs was M184, accounting for 39.64% ( 67 cases ) ; the main mutation sites associated with PIs were M46L/K, accounting for 2.96% ( 5 cases ) , resulting in high resistance to NFV. Conclusions The drug resistance rate of HIV-infected MSM with failure of antiviral therapy in Yunnan Province is relatively high, with CRF01_AE as the main gene subtype of drug resistance. The drug resistance rate of NNRTIs is relatively high, especially NVP and EFV.
Key words: men who have sex with men    human immunodeficiency virus    antiviral therapy    genotype    drug resistance
收稿日期: 2020-05-08      修回日期: 2020-07-01     
中图分类号:  R512.91  
基金资助:十三五国家科技重大专项(2018ZX10721102-002); 云南省教育厅科学研究基金项目(2018JS252)
作者简介: 阮尉月清,硕士在读;共同第一作者刘家法,硕士,主管技师,主要从事艾滋病相关检测工作
通信作者: 董兴齐,E-mail:dongxq8001@126.com   
引用本文:   
阮尉月清, 刘家法, 张米, 李健健, 杨壁珲, 邓雪媚, 董兴齐. 云南省男男性行为人群HIV/AIDS病例抗病毒治疗失败基因型耐药分析[J]. 预防医学, 2020, 32(10): 987-991.
RUAN Weiyueqing, LIU Jiafa, ZHANG Mi, LI Jianjian, YANG Bihui, DENG Xuemei, Dong Xingqi. Genotypic drug resistance of HIV-infected MSM who failedin antiviral therapy in Yunnan Province. Preventive Medicine, 2020, 32(10): 987-991.
链接本文:  
https://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2020.10.004      或      https://www.zjyfyxzz.com/CN/Y2020/V32/I10/987
[1] 朱君娜. HIV基因分型以及耐药性的研究进展[J].中国临床医生杂志,2014,42(11):21-22,25.
[2] CLUTTER D S,JORDAN M R,BERTAGNOLIO S,et al.HIV-1 drug resistance and resistance testing[J]. Infect Genet Evol,2016,46:292-307.
[3] 吴亚松,马烨. 中国艾滋病病毒耐药现状[J/CD].新发传染病电子杂志,2019,4(3):181-184.
[4] 李健健,潘小满,张米,等.云南省2014—2016年抗病毒失败HIV/AIDS基因型耐药情况调查[J].中华疾病控制杂志,2019,23(9):1107-1113.
[5] 安靓,劳云飞,李田舒,等.云南省男男同性性传播HIV感染者抗病毒治疗分析[J].卫生软科学,2017,31(6):61-64.
[6] WENSING A M,VAN DE VIJVER D A,ANGARANO G,et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management[J].Infect Dis,2005,192(6):958-966.
[7] 严华美,赵琬,张星灿,等.上海市闵行区新发男男性行为(MSM)人群HIV感染者特征及分子流行病学研究[J].复旦学报(医学版),2019,46(2):187-192.
[8] 张兴亮,罗艳,丁建明,等. 2017年杭州市新确诊男男性行为人群HIV/AIDS病例特征分析[J].预防医学,2020,32(4):373-377.
[9] 代丽丽,李在村,刘安,等.北京地区男男性行为人群 HIV 感染者中传播耐药状况[J].中国艾滋病性病,2015,21(12):1033-1037.
[10] 中国疾病预防控制中心性病艾滋病预防控制中心.国家免费艾滋病抗病毒药物治疗手册(第三版)[M].北京:人民卫生出版社,2012.
[11] 刘家法,李健健,杨壁珲,等. 2014—2015年云南省文山州HIV-1毒株耐药基因变异研究[J].国际检验医学杂志, 2017, 38(3): 307-310.
[12] 何惊春,凌华,张敏,等.重庆市男男性接触者HIV-1感染者原发耐药性分析[J].现代医药卫生,2018,34(10):1459-1461.
[13] 舒远路,杨翠先,张米,等.云南省HIV-1主要流行亚型毒株的耐药突变分析[J].中国艾滋病性病,2018,24(11):1080-1084,1114.
[14] 胡桂林,陈先刚,李向东,等.重庆主城区MSM人群HIV感染及影响因素分析[J].现代医药卫生,2020,36(4):498-502.
[15] YU D B,SUTHERLAND D,GHIDINELLI M,et al.HIV drug resistance assessment in the Western Pacific region. A systematic review.[J]. AIDS Rev,2011,13(4):214-226.
[16] ZHANG L,WANG Y J,WANG B X,et al.Prevalence of HIV-1 subtypes among men who have sex with men in China: a systematic review[J].Int J STD AIDS,2015,26(5):291-305.
[17] LI Y J, HAN Y, XIE J, et al.CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission[J]. AIDS,2014,28(4):521-530.
[18] CHEN M,MA Y L,SU Y Z,et al.HIV-1 genetic characteristics and transmitted drug resistance among men who have sex with men in Kunming, China[J].PLoS One,2014(9):e87033.
[19] CHEN M,JIA M H,MA Y L,et al.The changing HIV-1 genetic characteristics and transmitted drug resistance among recently infected population in Yunnan, China[J]. Epidemiol Infect,2018,146(6):775-781.
[20] SUI H,GUI T,JIA L,et al.Different frequencies of drug resistance mutations among HIV-1 subtypes circulating in China: a comprehensive study[J].PLoS One,2014,9(3):e91803.
[21] 邓雪媚,刘家法,张米,等.2011—2018年临沧市抗HIV-1治疗失败患者基因突变位点分析[J].中华疾病控制杂志,2019,23(12):1429-1435,1465.
[22] ARIFFIN T A,MOHAMAD S,YUSUF W N,et al.Antiretroviral drug resistance and HIV-1 subtypes among treatment-naïve prisoners in Kelantan, Malayasia[J]. J Infect Dev Ctries,2014,8(8):1063-1067.
[23] 袁丹,叶黎,龚芳红,等.2014年四川省部分地区HIV/AIDS患者抗病毒治疗效果和耐药性影响因素分析[J].现代预防医学,2016,43(13):2445-2452.
[1] 苏德华, 陈向阳, 李君, 赵丽娜, 张鹤美, 朱婷婷, 胡文雪, 赖江宜. 温州市新报告HIV/AIDS病例抗病毒治疗及时性分析[J]. 预防医学, 2025, 37(8): 804-808.
[2] 徐莉, 刘萍, 卞宇旬, 陈圆媛, 李鑫娜, 周乐. 扬州市新报告50岁及以上HIV/AIDS病例抗病毒治疗前耐药分析[J]. 预防医学, 2025, 37(8): 779-782,788.
[3] 周珊慧, 胡玉琴, 郑琼琼, 王晓红, 李毅, 项光新. 龙湾区食源性疾病沙门菌血清型及耐药性分析[J]. 预防医学, 2025, 37(7): 697-700,704.
[4] 江丽娜, 高丽, 王志锐, 王秀月, 戴文汐. 耐药基因突变结核分枝杆菌的sigma因子表达分析[J]. 预防医学, 2025, 37(6): 644-648.
[5] 黄银燕, 王勐, 徐翔. 纳米孔靶向测序技术鉴定分枝杆菌及分析结核分枝杆菌耐药性[J]. 预防医学, 2025, 37(6): 640-644,648.
[6] 孙玲, 刘元青, 刘新光, 张楠, 温婵, 郝建宗, 李梅. 河北省某儿童医院住院患儿多重耐药菌耐药性分析[J]. 预防医学, 2025, 37(6): 616-621.
[7] 白瑞盈, 生海燕. 肺炎住院患者多重耐药菌感染的预测模型研究[J]. 预防医学, 2025, 37(5): 465-470.
[8] 李瑶, 杨景元, 杨虹, 李向春, 孔瑞琴, 刘静, 白宝宝, 张艳萍, 李慧. 内蒙古自治区艾滋病自愿咨询检测门诊求询者特征分析[J]. 预防医学, 2025, 37(4): 356-360.
[9] 李倩, 杨柏林, 陈积标, 尹寒露, 许祝平, 孟晓军. 无锡市50岁及以上HIV/AIDS抗病毒治疗病例自报慢性病资料分析[J]. 预防医学, 2025, 37(4): 390-394.
[10] 王苓, 许珂, 张兴亮, 黄思超, 李西婷, 陈珺芳. 2022年杭州市新报告HIV/AIDS病例感染特征分析[J]. 预防医学, 2025, 37(2): 123-129.
[11] 马宵, 宁士龙. 1993—2021年中国归因于烟草的广泛耐药结核病疾病负担分析[J]. 预防医学, 2025, 37(12): 1266-1271.
[12] 丁晨, 刘家虹, 吴争, 熊长辉. 江西省部分地区HIV/AIDS病例HIV-1分子传播网络分析[J]. 预防医学, 2024, 36(9): 764-767.
[13] 李卫丹, 张子根. 一起利福平耐药肺结核聚集性疫情的流行病学调查[J]. 预防医学, 2024, 36(7): 630-632,635.
[14] 唐小芬, 秦道新, 金凤霞, 田园, 邹永霞, 沈玉蓉, 刘瑶, 谢秀钗. 2012—2022年罗湖区肺结核患者利福平和异烟肼耐药分析[J]. 预防医学, 2024, 36(6): 536-539.
[15] 贾晓锋, 王慧群, 石敏, 汤婕, 任静霞. HIV/AIDS病例HIV相关神经认知障碍的影响因素分析[J]. 预防医学, 2024, 36(6): 461-464.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed